Circulating miRNA signature for early diagnosis of lung cancer.
Circulating miRNA signature for early diagnosis of lung cancer.
复制标题
DOI:
10.1002/emmm.201100155
复制
发表时间:
2011-08
影响因子:
11.1
通讯作者:
Yang, Pan-Chyr
中科院分区:
文献类型:
--
作者:
Lin, Pei-Ying;Yang, Pan-Chyr
Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. Despite the numerous recent studies on NSCLC genomics, molecular mechanisms of disease and the development of targeted therapies, which improve treatment responses to a certain extent, the overall 5-year survival rate is only around 10–15%. The main reason for such a low 5-year survival rate has long been attributed to late diagnosis of the disease in three quarters of patients, resulting in advanced and inoperable diseases. Lung cancer studies for decades have attempted to develop screening modalities that allow early diagnosis. However, in contrast to the success in prognostic and predictive biomarker research during the past 10 years, the progress in early lung cancer screening is still limited and restricted to imaging studies.Chest radiography and sputum cytology screening programs in the 1970s had failed to reduce cancer mortality. Lowdose spiral chest computed tomography (LDCT) screening trials carried out in the 2000s generally resulted in a significant increase in the number of early-stage lung cancer diagnoses, but without apparent reduction in development of advanced cancers or cancer mortality
登录
查看更多内容
影响因子:
8.8
作者:
通讯作者:
--
DOI:
10.1073/pnas.0804549105
发表时间:
2008-07-29
影响因子:
11.1
作者:
Mitchell, Patrick S.;Parkin, Rachael K.;Tewari, Muneesh
通讯作者:
Tewari, Muneesh
DOI:
10.1073/pnas.1100048108
发表时间:
2011-03-01
影响因子:
11.1
作者:
Boeri, Mattia;Verri, Carla;Sozzi, Gabriella
通讯作者:
Sozzi, Gabriella
影响因子:
51.1
作者:
Bach, Peter B.
通讯作者:
Bach, Peter B.